Potent P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS dual antiplatelet therapy (DAPT) randomized pilot trial
Study context
- Population
- Patients with STEMI who underwent successful primary percutaneous coronary intervention (PCI) of the culprit lesion with a newer-generation polymer-free drug-eluting-stent (DES)planned recruitment target ("aims to recruit a total of"), no results reported
- Participants
- 350 patients
- Planned comparison
- Potent P2Y12 inhibitor-based single antiplatelet therapy (SAPT) vs Standard DAPT
- Primary endpoint
- Primary efficacy endpoint: Major adverse cardiac and cerebrovascular events (MACCE) (composite of all-cause death, non-fatal myocardial re-infarction, non-fatal stroke, urgent target vessel revascularization, or definite/probable stent thrombosis); primary safety endpoint: Bleeding Academic Research Consortium (BARC) class 3 or 5 major bleeding
- Follow-up
- 12 months
Methodological detailsrandomized in a 1:1 ratio
- Randomized in a 1:1 ratio
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study conduct
- The first patient was enrolled on December 1, 2025.
- The study is designed to provide estimates of treatment effects and their precision to inform the design of a subsequent larger randomized trial.
Original publication
Potent P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial. Am Heart J. Published 1 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →